Showing 1161-1170 of 1328 results for "".
- Vitals Report: National Average Wait Time Down Nearly 10% since 2009https://practicaldermatology.com/news/vitals-report-national-average-wait-time-down-nearly-10-since-2009/2458630/When it comes to waiting for a doctor’s appointment, most patients are waiting 19 minutes, 19 seconds, according to Vitals 7th annual wait time report This is down nearly 10 percent from the average 21 minutes and 18 seconds patients once sp
- Valeant Announces CEO Succession Plan And Changes To Board; Provides Accounting And Financial Reporting Updatehttps://practicaldermatology.com/news/valeant-announces-ceo-succession-plan-and-changes-to-board-provides-accounting-and-financial-reporting-update/2458640/Valeant’s board has initiated a search to identify a candidate to succeed J. Michael Pearson as chief executive officer (CEO). Mr. Pearson will continue to serve as CEO and a director until his replacement is appointed. The company also announced that William A. Ackman, CEO of Persh
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a
- Revance Therapeutics Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Developmenthttps://practicaldermatology.com/news/revance-therapeutics-appoints-roman-g-rubio-md-mba-as-senior-vice-president-of-clinical-development/2458649/Revance Therapeutics, Inc. has named Roman G. Rubio, MD, MBA Senior Vice President of Clinical Development. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company’s clinical development team, focusing on further accelerating the advancement of Reva
- Estée Lauder's Newest Collection Embraces Gen Yhttps://practicaldermatology.com/news/este-lauders-newest-collection-embraces-gen-y/2458652/Estee Lauder’s latest collection is all about the millennials. Fronted by guest editors Kendall Jenner and Irene Kim, the Estée Edit by Estée Lauder comprises 82 makeup and skincare products. The collection is inspired by Estée&rs
- Practical Dermatology® Launches #PDGivesBack to Support Camp Discovery at AAD 2016https://practicaldermatology.com/news/practical-dermatology-launches-pdgivesback-to-support-camp-discovery-at-aad-2016/2458672/Bryn Mawr Communications III’s Practical Dermatology® magazine is inviting attendees at the 74th Annual Meeting of the American Academy of Dermatology (AAD) to give back as part of its new “selfless-selfies” campaign.
- Novel Nanotechnology Delivery System May Offer New Approach to Skin Disease Treatmenthttps://practicaldermatology.com/news/novel-nanotechnology-delivery-system-may-offer-new-approach-to-skin-disease-treatment/2458675/A new nanotechnology-based delivery system may help activate the body's natural defense against free radicals and control a variety of skin conditions, report researchers from The Hebrew University of Jerusalem and Technion -- Israel Institute of Technology. Specifically, applyi
- FDA Approves Allergan's Aczone Gel, 7.5% for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-allergans-aczone-gel-75-for-acne-vulgaris/2458681/The FDA approved Allergn’s Aczone (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older. Aczone Gel, 7.5% delivers proven efficacy to treat both inflammatory and non-inflammatory acne, with a new concentration of dapsone in just once-a-day
- NOVAN: First Patient Dosed in Phase 3 Program for SB204https://practicaldermatology.com/news/novan-first-patient-dosed-in-phase-3-program-for-sb204/2458688/The first patient has been dosed in a Phase 3 study of Novan’s investigational topical nitric oxide acne gel, Novan, Inc. reports. Novan is running two identically designed Phase 3 pivotal trials in parallel to evaluate the effic
- Botox Helps Fuel Allergan's “Better-Than-Expected” Q4 Earningshttps://practicaldermatology.com/news/botox-helps-fuel-allergans-better-than-expected-q4-earnings/2458687/Allergan is reporting “better-than-expected” fourth-quarter earnings, largely fueled by Botox. The company saw a 74 percent increase in Q4 net revenue to $4.2 Billion for Q4 2015, topping the nearly $4.18 billion consensus estimate of S&a